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The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) path-
way is activated in the majority of human cancers.This pathway is known to play a key role
in numerous cellular functions including proliferation, adhesion, migration, invasion, metab-
olism, and survival, but in the current review we focus on its role in angiogenesis. PI3K
activation may occur via RAS mutation, loss of phosphatase and tensin homolog (PTEN), or
by increased expression of growth factor receptors such as epidermal growth factor recep-
tor.There is a connection between the PI3K pathway and angiogenesis. Hypoxia leads to
HIF-1α stabilization and is a major stimulus for increased vascular endothelial growth factor
(VEGF) production by tumor cells. However, activation of the PI3K/AKT pathway in tumor
cells can also increase VEGF secretion, both by hypoxia-inducible factor 1 (HIF-1) depen-
dent and independent mechanisms.The PI3K/AKT pathway also modulates the expression
of other angiogenic factors such as nitric oxide and angiopoietins. Numerous inhibitors
targeting the PI3K/AKT/mTOR pathway have been developed, and these agents have been
shown to decrease VEGF secretion and angiogenesis. The effect of these inhibitors on
tumor vasculature can be difﬁcult to predict.The vasculature of tumors is aberrant, leading
to sluggish bloodﬂow and elevated interstitial blood pressure, which can be perpetuated by
the high levels ofVEGF . Hence, decreasingVEGF expression can paradoxically lead to vas-
cular normalization and improved bloodﬂow in some tumors. In addition to its importance
in cancer, the PI3K pathway also plays an essential role in the formation of normal blood
vessels during development. Embryos with kinase-dead p110α catalytic subunit of PI3K
develop vascular defects. Stimulation of endothelial cells byVEGF leads to activation of the
PI3K pathway within these cells, which is important for cell migration. Sustained endothe-
lial activation of AKT1 has been shown to induce the formation of structurally abnormal
blood vessels that recapitulate the aberrations of tumor vessels. Hence, the PI3K pathway
plays an important role in regulating angiogenesis both in normal tissues and in cancers.
Keywords: angiogenesis, PI3K/AKT/mTOR,VEGF, nitric oxide, angiopoietins
INTRODUCTION
The PI3K/AKT pathway is important not only in the develop-
ment of cancers but also for signaling in normal cells. This path-
way is known to play a key role in numerous cellular functions
including proliferation, adhesion, migration, invasion, metabo-
lism,andsurvival(Baderetal.,2005),butinthecurrentreviewwe
focus on its role in angiogenesis. Phosphatidylinositol 3-kinases
(PI3K) are a family of enzymes that phosphorylate the 3 -OH of
the inositol ring of phosphatidylinositol. There are three classes
of PI3K: I, II, and III. Class I PI3Ks are heterodimers com-
posed of a catalytic and a regulatory subunit and are further
subdivided into two subclasses: IA and IB. Class II PI3Ks con-
sists of three members, P13KC2α, Pl3KC2β, and P13KC2γ, while
Class III contains only one member encoded by the gene VpS34
(Rodriguez-Viciana et al., 1994; Toker and Cantley, 1997; Fru-
man et al., 1998). Phosphatidylinositol 3,4,5-triphosphate (PIP3)
is an important lipid second messenger generated by PI3K,
which plays a vital role in several signal transduction pathways
(Whitman et al., 1988; Toker and Cantley, 1997). PIP3 activates
the serine/threonine kinases PDKl and AKT. The phosphatase
and tensin homolog (PTEN) gene encodes a phosphatase that
opposes the action of PI3K, thereby reducing the level of acti-
vated AKT. AKT controls protein synthesis and cell growth by
leadingtothephosphorylationofmammaliantargetofrapamycin
(mTOR).
Vascular endothelial growth factor (VEGF) is a potent angio-
genic factor whose effects on endothelial cells are mediated
in part by the PI3K pathway. The mammalian VEGF fam-
ily is comprised of ﬁve members: VEGFA, VEGFB, VEGFC,
VEGFD, and placenta growth factor (PGF), the best character-
ized of which is VEGFA, commonly referred to as simply VEGF.
A number of proteins structurally related to VEGF have also
been discovered encoded by parapoxviruses (VEGFE) and in
snake venom (VEGFF). The VEGF ligands can bind to three
type III receptor tyrosine kinases: VEGFRl/FLT1, VEGFR2/KDR,
and VEGFR3/FLT4, of which VEGFR2 has the most important
role in VEGF-induced angiogenesis (Ellis and Hicklin, 2008).
VEGFA, B and PGF can bind to VEGFR1. VEGFA and E bind
to VEGFR2, while VEGFC and D bind to VEGFR3 (Olsson et al.,
2006).
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TUMOR VASCULATURE AND REGULATION OF VEGF BY
HYPOXIA
The vasculature of tumors is aberrant, resulting in heterogene-
ity in the tumor microenvironment with variation in oxygen
concentration, nutritional factors, and metabolic waste products
(Vaupel et al., 1989). Tumor angiogenesis results from an imbal-
ance between pro-angiogenic factors such as VEGF and endoge-
nous anti-angiogenic factors such as angiostatin and endostatin
(Folkman, 2002; Nieder et al., 2006). Tumor cells vary in their
angiogenic potential,and angiogenic tumor cells generally secrete
more bFGF andVEGF than non-angiogenic ones (Naumov et al.,
2006). Elevated levels of VEGF can increase vascular permeability,
leadingtoleakyvessels,sluggishbloodﬂow,andelevatedinterstitial
pressure.
One of the most potent stimuli for increased VEGF produc-
tionbytumorcellsishypoxia,whichcommonlyoccursintumors.
Hypoxialeadstotheinductionofhypoxia-induciblefactor1(HIF-
1), a bHLH–PAS transcription factor that consists of both an α
and a β subunit (Ratcliffe et al., 2000; Semenza, 2003). Decreased
pO2 increases HIF-1α stability through post-translational mod-
iﬁcation of the protein. Once stabilized, the α subunit binds to
the β subunit, which is constitutively present. This heterodimer
then binds to numerous promoters containing hypoxia response
elements (HREs), leading to the transcription of dozens of target
genes including VEGF (Forsythe et al., 1996). HIF-1α is upreg-
ulated across a broad range of cancers, and HIF regulates key
features of tumor biology such as angiogenesis, invasion, and
glucose metabolism (Ratcliffe et al., 2000; Semenza, 2003).
Studies have shown that binding of both STAT3 and HIF-1α
to the VEGF promoter is essential for maximum transcription of
VEGF mRNA under hypoxia (Gray et al., 2005). STAT3 signaling
is required for VEGF and PI3K/AKT mediated HIF-1α expres-
sion. Blocking STAT3 by the small molecule inhibitor, CPA-7 or
STAT3 siRNA abolished both HIF-1 and VEGF expression (Xu
et al., 2005). EGF-induced STAT3 binding to the VEGF promoter
can be blocked by the PI3K inhibitor, LY294002, or STAT3 siRNA
in colorectal cancer cells (Cascio et al.,2009).
EGFR/PI3K/mTOR PATHWAY, HIF, AND VEGF
While hypoxia is the primary stimulus for HIF-1α upregulation,
activationoftheepidermalgrowthfactorreceptor(EGFR),andthe
PI3K pathway can also contribute to increased HIF-1α (Figure1).
EGFRisatransmembranereceptortyrosinekinasethatbelongsto
the HER family of receptors. It is overexpressed and activated in a
variety of cancers and provides an attractive target for anti-cancer
therapy (Dutta and Maity,2007). Zhong et al. (2000) were among
the ﬁrst to show that activation of the EGFR/PI3K/AKT/mTOR
pathwaycouldincreaseVEGFexpressionbyupregulatingHIF-1α.
PI3K/mTOR pathway activation increases HIF-1α protein lev-
els without altering HIF-1α mRNA levels (Jiang et al., 2001),
presumably by increasing HIF-1α translation (Laughner et al.,
2001).
Work from our own lab has shown that in U87MG human
glioblastomacells,EGFRactivationcanalsoincreaseVEGFexpres-
sionbytranscriptionalactivationoftheVEGFpromoterviaaPI3K
dependent pathway that is independent of HIF-1 (Maity et al.,
2000). We have also shown that EGFR ampliﬁcation and PTEN
FIGURE 1 | PI3K/AKT/mTOR pathway in angiogenesis. PI3K activation
may occur via RAS mutation, by increased expression of growth factor
receptors such as EGFR or by loss of PTEN. Activation of the
PI3K/AKT/mTOR pathway can increase VEGF secretion.The PI3K/AKT
pathway also modulates the expression of other angiogenic factors such as
nitric oxide and angiopoietins.
mutation had an additive effect in increasing the VEGF promoter
activity in human glioblastoma cells (Pore et al.,2003).
Pharmacological inhibition of EGFR can decrease VEGF
expression and reduce angiogenesis in many tumor types (Per-
rotte et al., 1999; Ciardiello et al., 2001; Huang et al., 2002; Pore
etal.,2006b).OneoftheinitialreportsexaminingEGFRinhibitors
found that the anti-EGFR antibody C225 could decrease not only
levels of VEGF mRNA and protein but that of other angiogenic
factors such as interleukin 8 and bFGF (Petit et al., 1997; Per-
rotte et al., 1999). One report showed that cells could acquire
resistance to this antibody by selection of tumor cell subpopu-
lations with increased angiogenic potential (Viloria-Petit et al.,
2001). The consequences of decreasing VEGF by blocking EGFR
signaling may be complicated. We have also shown that target-
ing tumor cells with the EGFR inhibitor erlotinib may improve
vascular ﬂow by causing vascular normalization, hence leading
to improved response to chemotherapy and radiation (Cerniglia
et al.,2009).
Epidermalgrowthfactorreceptoractivationmayhaveeffectson
VEGF expression independent of PI3K. A recent study exploring
theroleof MAPKandPI3Ksignalinginangiogenesisinsquamous
cell carcinoma of the head and neck found that EGFR activation
induces VEGFA expression that requires both PI3K and MAPK
signalingwhereasVEGFCexpressionisdependentonMAPK,and
not the PI3K–mTOR pathway (Luangdilok et al.,2011).
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Another common mechanism of PI3K activation within
tumors is through loss of PTEN which in glioblastomas results
in increased VEGF expression mediated by HIF-1α stabiliza-
tion (Zundel et al., 2000). PTEN loss is also seen in advanced
prostate cancers. PTEN siRNA transfected pancreatic cancer cells
have higher levels of secreted VEGF and are highly prolifera-
tive (Ma et al., 2009). Overexpression of wildtype PTEN in PC3
prostate cancer cells,which have PTEN mutations,inhibits angio-
genesis, and tumor growth (Fang et al., 2007). A recent study
exploring the role of PTEN in hepatocellular carcinoma also
found similar inhibition of angiogenesis. Interestingly, this study
also suggested that PTEN regulates angiogenesis through both
phosphatase-dependentandindependentmechanisms(Tianetal.,
2010).
RAS SIGNALING AND VEGF
TheRASfamilyof GTPases(H-RAS,N-RAS,andK-RAS)playsan
important role in various cellular functions, including prolifera-
tion, differentiation, and apoptosis. Mutations in H-RAS, K-RAS,
and N-RAS convert them into oncogenes,which commonly occur
invariouscancers(Bos,1989).Expressionof mutantK-RASorH-
RAS has been associated with increasedVEGF expression (Grugel
et al., 1995; Rak et al., 1995). Mazure et al. (1997) showed that
inductionofVEGFbyhypoxiaismodulatedbyaPI3K/AKTpath-
way in H-RAS transformed cells through a HIF-1 transcriptional
element. Introduction of oncogenic H-RAS into immortalized
endothelial cells increases their angiogenic potential and results
in increasedVEGF expression. This angiogenic potential could be
only partially inhibited by PI3K inhibition, indicating that RAS
mediated angiogenesis through a PI3K-independent mechanism
as well (Arbiser et al., 1997). H-RAS was found to play an impor-
tant role in angiogenesis in skin carcinogenesis. In this model,
H-RAS was responsible not only forVEGF induction,but also for
inducing the expression of other angiogenic factors such as PGF
and angiopoietin-2 (Larcher et al., 1996, 2003). Work from our
lab has shown that H-RAS upregulates Glut1 promoter activity,at
least in part, by increasing HIF-1α protein and that this involves
the PI3K pathway (Chen et al., 2001).
ROLE OF PI3K IN NORMAL DEVELOPMENT AND
ENDOTHELIAL CELLS
The PI3K pathway also plays an essential role in the forma-
tion of normal blood vessels during development. Embryos with
kinase-dead p110α catalytic subunit of PI3K develop gross vascu-
lar defects, indicating that this subunit is essential for endothelial
cell migration and angiogenesis (Graupera et al.,2008). The same
study showed that p110α controls endothelial cell migration by
positively regulating RhoA in endothelial cells. The p110α sub-
unit also regulates barrier function and junctional morphology of
endothelial cells. Only the p110α subunit decreased TNF-induced
endothelialcellpermeability,Tyrphosphorylationof theadherens
junction protein vascular endothelial cadherin, and leukocyte
transendothelial migration (Cain et al.,2010).
When VEGF binds to its receptor on normal endothelial cells,
theRASandPI3Kpathwaysareactivated.Onestudytriedtoiden-
tify vascular signaling in response to H-RAS and its immediate
effectors by activating either the ERK/MAPK or PI3K pathways in
primaryendothelialtissues(Serbanetal.,2008).Constitutiveacti-
vation of the ERK/MAPK pathway could induce angiogenesis but
not vascular permeability, while activation of PI3K was required
for both angiogenesis and vascular permeability. Pharmacological
inhibition of PI3K (α/β) suppressed both RAS or VEGF medi-
ated vascular response in vivo and survival of primary endothelial
cells in vitro. However, inhibition of PI3K (γ/δ) suppressed RAS
orVEGF mediated vascular permeability in vivo,with no effect on
the survival of primary endothelial cells.
Phosphataseandtensinhomolog,aphosphatasethatnegatively
regulates PI3K, has been found to be indispensable for normal
cardiovascular homeostasis. PTEN-deﬁcient endothelial cells dis-
play increased angiogenesis and tumorigenesis (Hamada et al.,
2005). The PDKl kinase is an essential player in the PI3K path-
way, phosphorylating AKT on the T308 residue. PDKl is vital to
endothelial cell migration in response to VEGF stimulation in
a PI3K-dependent manner (Primo et al., 2007). The study also
identiﬁedthatphosphorylationatT308ismoreimportantthanat
S473.
Arecentstudyfoundthatattenuatingtheexpressionof RACKl,
a ubiquitously expressed scaffolding protein, with siRNA sup-
pressedtheVEGF/PI3K/AKTdrivenmigrationof endothelialcells
(Wang et al., 2011). Survivin, an anti-apoptotic protein, is also
regulated by the PI3K pathway (Martinelli et al.,2006; Zhao et al.,
2010) and is upregulated in endothelial cells in response toVEGF
(Tran et al., 1999). Lack of survivin in endothelial cells has been
shown to result in embryonic defects in angiogenesis (Zwerts
et al., 2007). VEGF and survivin can act as chemoprotectants in
endothelial cells, protecting them from drug-induced dell death.
This chemoprotective role requires an active PI3K/AKT pathway
(Tran et al.,2002).
Sustained endothelia1 activation of AKTl has been shown to
induce the formation of structurally and functionally abnormal
blood vessels that recapitulate the aberrations of tumor vessels
(Phungetal.,2006).ThisstudyalsoshowedthatinhibitionofAKT
signalingbyrapamycincouldinhibitthepathologicalvasculariza-
tion.Inarecentstudy,sustainedRASactivationinendothelialcells
bypassed senescence and resulted in abnormal vascular morpho-
genesis,an effect that was regulated by PI3K signaling (Bajaj et al.,
2010).
Ephrinsandtheirreceptortyrosinekinasesplaysigniﬁcantroles
in various processes such as vascular development, cell migra-
tion, and angiogenesis. There are two classes of Eph receptors,
A and B. Class A receptors usually bind to GPI anchored ephrin
A ligands, and class B receptors bind to transmembrane-linked
ephrin B ligands. Binding of ephrin to the Eph receptor results
in bidirectional signaling between the receptor-carrying cell and
theligand-producingcell(PitulescuandAdams,2010).EphrinB2
controls the internalization of VEGFR2 and VEGFR3, a process
that is crucial for the growth of blood vessels (Sawamiphak et al.,
2010; Wang et al., 2010). In the absence of ligands, EphA2 recep-
tor can be phosphorylated by AKT, promoting cell migration
while in the presence of Ephrin A1, both AKT and the EphA2
receptor are dephosphorylated, preventing cell migration (Miao
et al., 2009). Slit and Robo proteins are regulators of vascular
remodeling.Slit2proteincanpromoteangiogenesisviamTORC2-
dependent activation of AKT and RAC. However, this process is
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inhibited in the presence of Ephrin A1, suggesting that the sig-
naling between Ephrin A1 and Slit can regulate angiogenesis and
vascular homeostasis (Dunaway et al.,2011).
PI3K/AKT AND NITRIC OXIDE
The PI3K/AKT pathway has also been implicated in angiogenesis
throughitsregulationofnitricoxide(NO)signalinginendothelial
cells.NitricoxidesynthesisisregulatedbytheenzymeNOsynthase
(NOS). There are three isoforms of NOS, of which nNOS/NOS1
and eNOS/NOS3 are constitutively expressed,while expression of
the third isoform, iNOS/NOS2, is inducible. Tumor cells mostly
expressiNOS,butsometumortypesalsoexpresseNOSandnNOS.
Tumor vascular endothelial cells mostly express eNOS, while the
tumor associated stromal ﬁbroblasts and immune cells express
iNOS (Fukumura et al., 2006).
Studies using eNOS−/− and iNOS−/− mice have shown that
eNOS plays a key role in VEGF-induced angiogenesis and vas-
cular permeability (Fukumura et al., 2001). VEGF stimulation of
endothelialcellsisrequiredforthemigrationof thesecellsandthe
formation of capillary-like structures in a PI3K–AKT dependent
manner (Morales-Ruiz et al., 2000). Earlier studies have shown
that VEGF can induce NO production, which is attenuated by
PI3K inhibitors (Papapetropoulos et al., 1997). This regulation
mayoccurviaphosphorylationof eNOSattheserine1177residue
by AKT (Dimmeler et al., 1999; Fulton et al., 1999). This phos-
phorylation is required forVEGF-induced endothelial cell migra-
tion (Dimmeler et al., 2000). Hypoxia can also increase eNOS
phosphorylation via HSP9O binding to eNOS and activation of
the PI3K/AKT pathway (Chen and Meyrick, 2004). Another link
between the NO pathway and angiogenesis is suggested by the
fact that NO donors can increase the expression and transcrip-
tional activity of HIF-1, thus resulting in the induction of VEGF
mRNA(Kasunoetal.,2004).Thesamestudyreportedthattarget-
ing the PI3K pathway using LY294002 or rapamycin inhibited the
expression of HIF-1 dependent reporter gene induced by the NO
donor.
ANGIOPOIETINS
In addition to VEGF, another class of growth factors having
angiogenic activity includes the angiopoietins and their receptors,
especially the ANGl/TIE2 system. Angiopoietin 1 and 2 (ANG1
and 2) bind to TIE2 receptor tyrosine kinase, which is expressed
primarilyonendothelialcells.WhileANGlisrequiredforendothe-
lial development, ANG2 is an antagonist of the ANGl/TIE2 sys-
tem and can disrupt blood vessel formation (Davis et al., 1996;
Maisonpierreetal.,1997).However,somereportsalsosuggestthat
ANG2 can be pro-angiogenic in some circumstances. ANG2 can
promote proliferation and migration of endothelial cells, sprout-
ing, and neovascularization in the presence of VEGF (Asahara
et al., 1998; Lobov et al., 2002). A study using ANGl or ANG2
inhibitors reported that while ANG1 inhibition had little effect
on the tumor vasculature, ANG2 inhibition resulted in decreased
tumor vascularity and allowed for unrestricted ANGl activity,
leading to vessel normalization. TheANGl–ANG2 inhibitor com-
bination did not affect the ANG2-mediated inhibition of vascu-
lature but prevented tumor vessel normalization (Falcon et al.,
2009).
ANG1 can promote endothelial cell survival through activa-
tion of the PI3K pathway (Kim et al., 2000a), and similar results
couldbeachievedwithhigherconcentrationsofANG2(Kimetal.,
2000b) .Ar e c e n ts t u d yb yYuan et al. (2009) showed that ANG2
can act as an agonist of the TIE2 receptor in the absence of ANGl
and can activate the PI3K–AKT pathway, although with weaker
potency than ANGl. ANGl has been shown to stimulate TIE2,
AKT, and eNOS phosphorylation in HUVECs in a PI3K depen-
dent manner (Babaei et al., 2003). Another study reported that
HSP90 binding to eNOS and activation of the PI3K pathway con-
tribute toANGl induced eNOS phosphorylation,NO production,
and angiogenesis in coronary artery endothelial cells (Chen et al.,
2004). Mice lacking the p110α catalytic subunit of PI3K display
vascular defects along with reduced TIE2 protein levels (Lelievre
et al., 2005). It has been shown that association between p85
subunit of PI3K and TIE2 is essential for PI3K activity (Kontos
et al., 1998). ANGl can induce localization of TIE2 to endothe-
lial cell–cell contacts, however in isolated cells TIE2 localizes to
cell–substratum contacts (Fukuhara et al., 2008; Saharinen et al.,
2008). TIE2 activation at cell–cell contacts leads to the activation
of AKT,which results in phosphorylation of eNOS and inhibition
ofFOXO1(Fukuharaetal.,2008).FOXO1regulatestheexpression
of genes involved in apoptosis such as survivin and also regulates
the expression of ANG2 (ANG1 antagonist) in endothelial cells,
suggesting the importance of ANGl in maintaining blood vessel
stability (Daly et al., 2004). The ANG1–TIE2 association also reg-
ulates the expression of D114,a Notch ligand involved in vascular
stability in a β-catenin dependent manner. PI3K–AKT inhibits
GSK3β leading to β-catenin stability and this potentiates Notch
signal-mediated D114 expression (Zhang et al.,2011).
PI3K/AKT/mTOR INHIBITORS
Inhibitors targeting the PI3K/AKT pathway have been developed
and, as predicted, these agents can decrease VEGF secretion and
angiogenesis. The traditional PI3K/AKT inhibitors LY294002 and
wortmannin exhibit anti-angiogenic activity. However, LY294002
and wortmannin are unsuitable for human use due to toxicity.
Newer PI3K inhibitors including SF1126 (Garlich et al., 2008),
ZSTK474(Kongetal.,2009),andPI103(Raynaudetal.,2007)have
displayedanti-angiogenicactivityinxenograftmodels.TheNovar-
tis drug NVP-BEZ235, which is a dual PI3K and mTOR inhibitor
(Maira et al.,2008),blockedVEGF-induced neovascularization in
mice (Schnell et al., 2008), and inhibited the growth and prolifer-
ation of cancer cells with wild type and p110α mutations (Serra
et al.,2008).We have previously shown that nelﬁnavir,a HIV pro-
tease inhibitor can also inhibit AKT signaling and decrease VEGF
expression. Nelﬁnavir decreased the VEGF secretion under both
normoxic and hypoxic conditions (Pore et al.,2006a).
Inhibitors are also available against mTOR. mTOR kinase can
participateintwodifferentcomplexes:mTORC1(mTOR/Raptor)
and mTORC2 (mTOR/Rictor). Rapamycin is an mTORC1
inhibitor, and treatment with this agent or its analogs induces
insulin receptor substrate-1 expression, terminating the feed-
back inhibition of the pathway, and resulting in AKT activa-
tion (O’Reilly et al., 2006). However, with prolonged incuba-
tion, rapamycin may inhibit mTORC2 in certain cell types (Sar-
bassov et al., 2006). Rapamycin inhibits VEGF production and
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has antiproliferative and antitumor activity (Zhong et al., 2000;
Guba et al., 2002). The drug has also been shown to inhibit
angiogenesis in vivo (Guba et al., 2002). The TSC2–TSC1 pro-
tein complex negatively regulates mTOR. TSC2-null cells have
high levels of HIF-1α and VEGF. Rapamycin treatment reduces
HIF-1α levels but fails to reduce VEGF levels completely in these
cells, indicating that TSC2 regulates VEGF through both mTOR-
dependent and -independent pathways (Brugarolas et al., 2003).
TreatmentofmyrAKT1mice(withsustainedAKTactivation)with
rapamycinhasbeenshowntoblockbloodvesselformation(Phung
et al.,2006). The regulatory associated protein of mTOR (Raptor)
has been shown to interact with HIF-1α via an mTOR signal-
ing motif located in the N terminus of HIF-1α. HIF-1α lacking
this motif had impaired activity under hypoxia and was unable
to bind to the co-activator CBP/p300 (Land and Tee, 2007). The
dual mTORC1/mTORC2 inhibitors, OSI-027, and OXA-01 have
been shown to considerably reduce angiogenesis and regrowth
compared to rapamycin (mTORC1 inhibitor) alone. Combin-
ing these dual inhibitors with VEGFR antagonists was even more
efﬁcient in reducing tumor growth (Falcon et al., 2011).
SUMMARY
Activation of the PI3K/AKT/mTOR pathway in tumor cells can
increase VEGF secretion by both HIF-1 dependent and indepen-
dent mechanisms. This pathway can also regulate angiogenesis by
modulating expression of nitric oxide and angiopoietins. Many
agents have been developed that can inhibit PI3K and/or mTOR
signalingintumorcells,andthesedrugshaveeffectsonangiogen-
esis as well as on tumor cell proliferation and survival. Not only
is the PI3K/AKT/mTOR pathway commonly activated in tumor
cells,butVEGFbindingtoreceptorsonendothelialcellsstimulates
this pathway which is essential for endothelial cell migration. For
this reason the PI3K/AKT pathway is essential for normal blood
vessel development during embryogenesis.
REFERENCES
Arbiser, J. L., Moses, M. A., Fernan-
dez, C. A., Ghiso, N., Cao, Y.,
Klauber, N., Frank, D., Brownlee,
M., Flynn, E., Parangi, S., Byers, H.
R., and Folkman, J. (1997). Onco-
genicH-rasstimulatestumorangio-
genesis by two distinct pathways.
Proc. Natl. Acad. Sci. U.S.A. 94,
861–866.
Asahara, T., Chen, D., Takahashi, T.,
Fujikawa, K., Kearney, M., Magner,
M., Yancopoulos, G. D., and Isner,
J. M. (1998). Tie2 receptor ligands,
angiopoietin-1 and angiopoietin-2,
modulate VEGF-induced postnatal
neovascularization. Circ. Res. 83,
233–240.
Babaei, S., Teichert-Kuliszewska, K.,
Zhang, Q., Jones, N., Dumont,
D. J., and Stewart, D. J. (2003).
Angiogenic actions of angiopoietin-
1 require endothelium-derived
nitric oxide. Am. J. Pathol. 162,
1927–1936.
Bader,A.G.,Kang,S.,Zhao,L.,andVogt,
P. K. (2005). Oncogenic PI3K dereg-
ulates transcription and translation.
Nat. Rev. Cancer 5, 921–929.
Bajaj, A., Zheng, Q., Adam, A., Vin-
cent, P., and Pumiglia, K. (2010).
Activation of endothelial ras signal-
ing bypasses senescence and causes
abnormal vascular morphogenesis.
Cancer Res. 70, 3803–3812.
Bos, J. L. (1989). ras Oncogenes in
human cancer: a review. Cancer Res.
49, 4682–4689.
Brugarolas, J. B., Vazquez, F., Reddy,
A., Sellers, W. R., and Kaelin, W.
G. Jr. (2003). TSC2 regulates VEGF
through mTOR-dependent and -
independent pathways. Cancer Cell
4, 147–158.
Cain, R. J., Vanhaesebroeck, B., and
Ridley, A. J. (2010). The PI3K
p110alpha isoform regulates
endothelial adherens junctions via
Pyk2 and Rac1. J. Cell Biol. 188,
863–876.
Cascio, S., Ferla, R., D’Andrea, A.,
Gerbino, A., Bazan, V., Surmacz,
E., and Russo, A. (2009). Expres-
sion of angiogenic regulators,VEGF
and leptin, is regulated by the
EGF/PI3K/STAT3 pathway in col-
orectal cancer cells. J. Cell. Physiol.
221, 189–194.
Cerniglia, G. J., Pore, N., Tsai, J. H.,
Schultz, S., Mick, R., Choe, R., Xing,
X.,Durduran,T.,Yodh,A. G.,Evans,
S. M., Koch, C. J., Hahn, S. M.,
Quon, H., Sehgal, C. M., Lee, W.
M., and Maity, A. (2009). Epider-
mal growth factor receptor inhibi-
tion modulates the microenviron-
ment by vascular normalization to
improve chemotherapy and radio-
therapyefﬁcacy.PLoSONE 4,e6539.
doi:10.1371/journal.pone.0006539
Chen, C., Pore, N., Behrooz, A., Ismail-
Beigi, F., and Maity, A. (2001).
Regulation of glut1 mRNA by
hypoxia-inducible factor-1. Interac-
tion between H-ras and hypoxia.J .
Biol. Chem. 276, 9519–9525.
Chen, J. X., Lawrence, M. L., Cun-
ningham, G., Christman, B. W.,
and Meyrick, B. (2004). HSP90 and
AktmodulateAng-1-inducedangio-
genesis via NO in coronary artery
endothelium. J. Appl. Physiol. 96,
612–620.
Chen, J. X., and Meyrick, B. (2004).
Hypoxia increases Hsp90 binding to
eNOSviaPI3K-Aktinporcinecoro-
naryarteryendothelium.Lab.Invest.
84, 182–190.
Ciardiello, F., Caputo, R., Bianco, R.,
Damiano, V., Fontanini, G., Cuc-
cato, S., De, P. S., Bianco, A. R.,
andTortora,G.(2001).Inhibitionof
growthfactorproductionandangio-
genesis in human cancer cells by
ZD1839 (Iressa), a selective epider-
mal growth factor receptor tyrosine
kinase inhibitor. Clin. Cancer Res. 7,
1459–1465.
Daly, C., Wong, V., Burova, E., Wei,
Y., Zabski, S., Grifﬁths, J., Lai, K.
M., Lin, H. C., Ioffe, E., Yancopou-
los, G. D., and Rudge, J. S. (2004).
Angiopoietin-1 modulates endothe-
lial cell function and gene expres-
sion via the transcription factor
FKHR (FOXO1). Genes Dev. 18,
1060–1071.
Davis, S., Aldrich, T. H., Jones, P. F.,
Acheson, A., Compton, D. L., Jain,
V., Ryan, T. E., Bruno, J., Radziejew-
ski,C.,Maisonpierre,P. C.,andYan-
copoulos, G. D. (1996). Isolation of
angiopoietin-1,aligandfortheTIE2
receptor, by secretion-trap expres-
sion cloning. Cell 87, 1161–1169.
Dimmeler,S.,Dernbach,E.,and Zeiher,
A. M. (2000). Phosphorylation of
the endothelial nitric oxide synthase
at ser-1177 is required for VEGF-
induced endothelial cell migration.
FEBS Lett. 477, 258–262.
Dimmeler,S.,Fleming,I.,Fisslthaler,B.,
Hermann, C., Busse, R., and Zeiher,
A. M. (1999). Activation of nitric
oxide synthase in endothelial cells
by Akt-dependent phosphorylation.
Nature 399, 601–605.
Dunaway,C.M.,Hwang,Y.,Lindsley,C.
W., Cook, R. S., Wu, J. Y., Boothby,
M., Chen, J., and Brantley-Sieders,
D. M. (2011). Cooperative signaling
between Slit2 and Ephrin-A1 regu-
lates a balance between angiogenesis
and angiostasis. Mol. Cell. Biol. 31,
404–416.
Dutta,P.R.,andMaity,A.(2007).Cellu-
larresponsestoEGFRinhibitorsand
their relevance to cancer therapy.
Cancer Lett. 254, 165–177.
Ellis, L. M., and Hicklin, D. J.
(2008). VEGF-targeted therapy:
mechanismsofanti-tumouractivity.
Nat. Rev. Cancer 8, 579–591.
Falcon, B. L., Barr, S., Gokhale, P. C.,
Chou, J., Fogarty, J., Depeille, P.,
Miglarese, M., Epstein, D. M., and
McDonald, D. M. (2011). Reduced
VEGF production, angiogenesis,
and vascular regrowth contribute
to the antitumor properties of
dualmTORC1/mTORC2inhibitors.
Cancer Res. 71, 1573–1583.
Falcon,B.L.,Hashizume,H.,Koumout-
sakos, P., Chou, J., Bready, J. V.,
Coxon,A.,Oliner,J.D.,andMcDon-
ald, D. M. (2009). Contrasting
actions of selective inhibitors of
angiopoietin-1 and angiopoietin-2
on the normalization of tumor
blood vessels. Am. J. Pathol. 175,
2159–2170.
Fang, J., Ding, M., Yang, L., Liu,
L. Z., and Jiang, B. H. (2007).
PI3K/PTEN/AKT signaling regu-
lates prostate tumor angiogenesis.
Cell. Signal. 19, 2487–2497.
Folkman, J. (2002). Role of angiogene-
sis in tumor growth and metastasis.
Semin. Oncol. 29, 15–18.
Forsythe, J. A., Jiang, B. H., Iyer, N.
V., Agani, F., Leung, S. W., Koos,
R. D., and Semenza, G. L. (1996).
Activation of vascular endothelial
growth factor gene transcription
by hypoxia-inducible factor 1. Mol.
Cell. Biol. 16, 4604–4613.
Fruman,D. A.,Meyers,R. E.,and Cant-
ley, L. C. (1998). Phosphoinositide
kinases. Annu. Rev. Biochem. 67,
481–507.
Fukuhara, S., Sako, K., Minami, T.,
Noda, K., Kim, H. Z., Kodama, T.,
Shibuya, M., Takakura, N., Koh, G.
Y., and Mochizuki, N. (2008). Dif-
ferential function of Tie2 at cell-cell
contacts and cell-substratum con-
tacts regulated by angiopoietin-1.
Nat. Cell Biol. 10, 513–526.
Frontiers in Molecular Neuroscience www.frontiersin.org December 2011 | Volume 4 | Article 51 | 5Karar and Maity PI3K/AKT/mTOR pathway in angiogenesis
Fukumura, D., Gohongi, T., Kadambi,
A., Izumi, Y., Ang, J., Yun, C.
O., Buerk, D. G., Huang, P. L.,
and Jain, R. K. (2001). Predom-
inant role of endothelial nitric
oxide synthase in vascular endothe-
lial growth factor-induced angio-
genesis and vascular permeability.
Proc. Natl. Acad. Sci. U.S.A. 98,
2604–2609.
Fukumura, D., Kashiwagi, S., and Jain,
R. K. (2006). The role of nitric oxide
in tumour progression. Nat. Rev.
Cancer 6, 521–534.
Fulton, D., Gratton, J. P., McCabe, T.
J., Fontana, J., Fujio, Y., Walsh, K.,
Franke, T. F., Papapetropoulos, A.,
and Sessa, W. C. (1999). Regulation
of endothelium-derived nitric oxide
production by the protein kinase
Akt. Nature 399, 597–601.
Garlich, J. R., De, P., Dey, N., Su, J. D.,
Peng,X.,Miller,A.,Murali,R.,Lu,Y.,
Mills, G. B., Kundra, V., Shu, H. K.,
Peng, Q., and Durden, D. L. (2008).
A vascular targeted pan phospho-
inositide3-kinaseinhibitorprodrug,
SF1126, with antitumor and antian-
giogenic activity. Cancer Res. 68,
206–215.
Graupera, M., Guillermet-Guibert, J.,
Foukas, L. C., Phng, L. K., Cain, R.
J., Salpekar, A., Pearce, W., Meek,
S., Millan, J., Cutillas, P. R., Smith,
A. J., Ridley, A. J., Ruhrberg, C.,
Gerhardt, H., and Vanhaesebroeck,
B. (2008). Angiogenesis selectively
requires the p110alpha isoform of
PI3K to control endothelial cell
migration. Nature 453, 662–666.
Gray, M. J., Zhang, J., Ellis, L.
M., Semenza, G. L., Evans, D.
B., Watowich, S. S., and Gal-
lick, G. E. (2005). HIF-1alpha,
STAT3, CBP/p300 and Ref-1/APE
are components of a transcrip-
tional complex that regulates Src-
dependent hypoxia-induced expres-
sion of VEGF in pancreatic and
prostate carcinomas. Oncogene 24,
3110–3120.
Grugel,S.,Finkenzeller,G.,Weindel,K.,
Barleon, B., and Marme, D. (1995).
Both v-Ha-Ras and v-Raf stimulate
expression of the vascular endothe-
lial growth factor in NIH 3T3 cells.
J. Biol. Chem. 270, 25915–25919.
Guba, M., von Breitenbuch, P., Stein-
bauer, M., Koehl, G., Flegel, S.,
Hornung, M., Bruns, C. J., Zuelke,
C., Farkas, S., Anthuber, M., Jauch,
K. W., and Geissler, E. K. (2002).
Rapamycin inhibits primary and
metastatic tumor growth by antian-
giogenesis: involvement of vascular
endothelial growth factor. Nat. Med.
8, 128–135.
Hamada, K., Sasaki, T., Koni, P. A.,
Natsui, M., Kishimoto, H., Sasaki,
J., Yajima, N., Horie, Y., Hasegawa,
G., Naito, M., Miyazaki, J., Suda,
T., Itoh, H., Nakao, K., Mak, T. W.,
Nakano, T., and Suzuki, A. (2005).
The PTEN/PI3K pathway governs
normal vascular development and
tumor angiogenesis. Genes Dev. 19,
2054–2065.
Huang, S. M., Li, J., Armstrong, E.
A., and Harari, P. M. (2002). Mod-
ulation of radiation response and
tumor-induced angiogenesis after
epidermal growth factor receptor
inhibition by ZD1839 (Iressa). Can-
cer Res. 62, 4300–4306.
Jiang, B. H., Jiang, G., Zheng, J. Z., Lu,
Z.,Hunter,T.,andVogt,P.K.(2001).
Phosphatidylinositol 3-kinase sig-
naling controls levels of hypoxia-
inducible factor 1. Cell Growth Dif-
fer. 12, 363–369.
Kasuno, K., Takabuchi, S., Fukuda,
K., Kizaka-Kondoh, S., Yodoi, J.,
Adachi, T., Semenza, G. L., and
Hirota, K. (2004). Nitric oxide
induces hypoxia-inducible factor 1
activation that is dependent on
MAPK and phosphatidylinositol 3-
kinase signaling. J. Biol. Chem. 279,
2550–2558.
Kim,I.,Kim,H. G.,So,J. N.,Kim,J. H.,
Kwak, H. J., and Koh, G. Y. (2000a).
Angiopoietin-1 regulates endothe-
lial cell survival through the phos-
phatidylinositol 3 -Kinase/Akt sig-
nal transduction pathway. Circ. Res.
86, 24–29.
Kim, I., Kim, J. H., Moon, S. O., Kwak,
H. J., Kim, N. G., and Koh, G.
Y. (2000b). Angiopoietin-2 at high
concentrationcanenhanceendothe-
lial cell survival through the phos-
phatidylinositol3 -kinase/Aktsignal
transduction pathway. Oncogene 19,
4549–4552.
Kong, D., Okamura, M., Yoshimi, H.,
and Yamori, T. (2009). Antian-
giogenic effect of ZSTK474, a
novel phosphatidylinositol 3-kinase
inhibitor.Eur.J.Cancer 45,857–865.
Kontos, C. D., Stauffer, T. P., Yang, W.
P., York, J. D., Huang, L., Blanar,
M. A., Meyer, T., and Peters, K. G.
(1998). Tyrosine 1101 of Tie2 is the
major site of association of p85 and
is required for activation of phos-
phatidylinositol 3-kinase and Akt.
Mol. Cell. Biol. 18, 4131–4140.
Land, S. C., and Tee, A. R. (2007).
Hypoxia-inducible factor 1alpha is
regulated by the mammalian target
of rapamycin(mTOR)viaanmTOR
signaling motif. J. Biol. Chem. 282,
20534–20543.
Larcher, F., Franco, M., Bolontrade, M.,
Rodriguez-Puebla, M., Casanova,
L., Navarro, M., Yancopoulos,
G., Jorcano, J. L., and Conti,
C. J. (2003). Modulation of the
angiogenesis response through
Ha-ras control, placenta growth
factor, and angiopoietin expression
in mouse skin carcinogenesis. Mol.
Carcinog. 37, 83–90.
Larcher, F., Robles, A. I., Duran,
H., Murillas, R., Quintanilla, M.,
Cano, A., Conti, C. J., and Jor-
cano, J. L. (1996). Up-regulation
of vascular endothelial growth fac-
tor/vascular permeability factor in
mouseskincarcinogenesiscorrelates
with malignant progression state
and activated H-ras expression lev-
els. Cancer Res. 56, 5391–5396.
Laughner, E., Taghavi, P., Chiles,
K., Mahon, P. C., and Semenza,
G. L. (2001). HER2 (neu)
signaling increases the rate of
hypoxia-inducible factor 1alpha
(HIF-1alpha) synthesis: novel
mechanism for HIF-1-mediated
vascular endothelial growth factor
expression. Mol. Cell. Biol. 21,
3995–4004.
Lelievre, E., Bourbon, P. M., Duan,
L. J., Nussbaum, R. L., and Fong,
G. H. (2005). Deﬁciency in the
p110alpha subunit of PI3K results
in diminished Tie2 expression and
Tie2(-/-)-like vascular defects in
mice. Blood 105, 3935–3938.
Lobov, I. B., Brooks, P. C., and Lang,
R. A. (2002). Angiopoietin-2 dis-
plays VEGF-dependent modulation
of capillary structure and endothe-
lial cell survival in vivo. Proc. Natl.
Acad. Sci. U.S.A. 99, 11205–11210.
Luangdilok, S., Box, C., Harrington, K.,
Rhys-Evans,P.,andEccles,S.(2011).
MAPKandPI3Ksignallingdifferen-
tially regulate angiogenic and lym-
phangiogenic cytokine secretion in
squamouscellcarcinomaofthehead
andneck.Eur.J.Cancer 47,520–529.
Ma, J., Sawai, H., Ochi, N., Matsuo,
Y., Xu, D., Yasuda, A., Takahashi,
H., Wakasugi, T., and Takeyama, H.
(2009). PTEN regulates angiogene-
sis through PI3K/Akt/VEGF signal-
ing pathway in human pancreatic
cancer cells. Mol. Cell. Biochem. 331,
161–171.
Maira, S. M., Stauffer, F., Brueggen,
J., Furet, P., Schnell, C., Fritsch,
C., Brachmann, S., Chène, P., De
Pover, A., Schoemaker, K., Fab-
bro, D., Gabriel, D., Simonen,
M., Murphy, L., Finan, P., Sell-
ers, W., and García-Echeverría, C.
(2008). Identiﬁcation and charac-
terization of NVP-BEZ235, a new
orally available dual phosphatidyli-
nositol 3-kinase/mammalian target
of rapamycin inhibitor with potent
invivoantitumoractivity.Mol.Can-
cer Ther. 7, 1851–1863.
Maisonpierre, P. C., Suri, C., Jones,
P. F., Bartunkova, S., Wiegand,
S. J., Radziejewski, C., Compton,
D., McClain, J., Aldrich, T. H.,
Papadopoulos, N., Daly, T. J., Davis,
S., Sato, T. N., and Yancopoulos, G.
D. (1997). Angiopoietin-2, a nat-
uralantagonistforTie2thatdisrupts
in vivo angiogenesis. Science 277,
55–60.
Maity,A., Pore, N., Lee, J., Solomon, D.,
and O’Rourke, D. M. (2000). Epi-
dermal growth factor receptor tran-
scriptionally up-regulates vascular
endothelial growth factor expres-
sion in human glioblastoma cells via
a pathway involving phosphatidyli-
nositol 3 -kinase and distinct from
thatinducedbyhypoxia.CancerRes.
60, 5879–5886.
Martinelli, S., Kostylina, G., Niggli, V.,
Baumann, C., Fey, M. F., Wen-
del, H. G., Lowe, S. W., Youseﬁ,
S., and Simon, H. U. (2006). Tar-
geting survivin via PI3K but not
c-akt/PKB by anticancer drugs in
immatureneutrophils.Oncogene 25,
6915–6923.
Mazure, N. M., Chen, E. Y., Laderoute,
K. R., and Giaccia, A. J. (1997).
Induction of vascular endothe-
lial growth factor by hypoxia is
modulated by a phosphatidylinos-
itol 3-kinase/Akt signaling path-
way in Ha-ras-transformed cells
through a hypoxia inducible factor-
1 transcriptional element. Blood 90,
3322–3331.
Miao, H., Li, D. Q., Mukherjee, A.,
Guo, H., Petty, A., Cutter, J., Basil-
ion,J.P.,Sedor,J.,Wu,J.,Danielpour,
D., Sloan, A. E., Cohen, M. L., and
Wang, B. (2009). EphA2 mediates
ligand-dependent inhibition and
ligand-independent promotion of
cell migration and invasion via a
reciprocal regulatory loop with Akt.
Cancer Cell 16, 9–20.
Morales-Ruiz, M., Fulton, D., Sowa, G.,
Languino, L. R., Fujio, Y., Walsh,
K., and Sessa, W. C. (2000). Vas-
cular endothelial growth factor-
stimulated actin reorganization and
migration of endothelial cells is
regulated via the serine/threonine
kinase Akt. Circ. Res. 86, 892–896.
Naumov,G. N.,Bender,E.,Zurakowski,
D., Kang, S. Y., Sampson, D., Flynn,
E., Watnick, R. S., Straume, O.,
Akslen, L. A., Folkman, J., and
Almog, N. (2006). A model of
human tumor dormancy: an angio-
genic switch from the nonangio-
genicphenotype.J.Natl.CancerInst.
98, 316–325.
Nieder, C., Wiedenmann, N.,
Andratschke, N., and Molls, M.
(2006). Current status of angio-
genesis inhibitors combined with
radiation therapy. Cancer Treat. Rev.
32, 348–364.
Frontiers in Molecular Neuroscience www.frontiersin.org December 2011 | Volume 4 | Article 51 | 6Karar and Maity PI3K/AKT/mTOR pathway in angiogenesis
Olsson, A. K., Dimberg, A., Kreuger, J.,
and Claesson-Welsh, L. (2006).
VEGF receptor signalling -
in control of vascular func-
tion. Nat. Rev. Mol. Cell. Biol. 7,
359–371.
O’Reilly, K. E., Rojo, F., She, Q. B., Solit,
D., Mills, G. B., Smith, D., Lane, H.,
Hofmann, F., Hicklin, D. J., Lud-
wig, D. L., Baselga, J., and Rosen,
N.(2006).mTORinhibitioninduces
upstream receptor tyrosine kinase
signaling and activates Akt. Cancer
Res. 66, 1500–1508.
Papapetropoulos, A., Garcia-Cardena,
G., Madri, J. A., and Sessa, W. C.
(1997).Nitricoxideproductioncon-
tributes to the angiogenic properties
ofvascularendothelialgrowthfactor
in human endothelial cells. J. Clin.
Invest. 100, 3131–3139.
Perrotte, P., Matsumoto, T., Inoue, K.,
Kuniyasu, H., Eve, B. Y., Hicklin, D.
J., Radinsky, R., and Dinney, C. P.
(1999). Anti-epidermal growth fac-
tor receptor antibody C225 inhibits
angiogenesis in human transitional
cell carcinoma growing orthotopi-
cally in nude mice. Clin. Cancer Res.
5, 257–265.
Petit, A. M., Rak, J., Hung, M. C.,
Rockwell, P., Goldstein, N., Fendly,
B., and Kerbel, R. S. (1997). Neu-
tralizing antibodies against epider-
mal growth factor and ErbB-2/neu
receptor tyrosine kinases down-
regulate vascular endothelial growth
factor production by tumor cells
in vitro and in vivo: angiogenic
implications for signal transduction
therapy of solid tumors. Am. J.
Pathol. 151, 1523–1530.
Phung, T. L., Ziv, K., Dabydeen, D.,
Eyiah-Mensah, G., Riveros, M., Per-
ruzzi,C.,Sun,J.,Monahan-Earley,R.
A., Shiojima, I., Nagy, J. A., Lin, M.
I.,Walsh,K.,Dvorak,A. M.,Briscoe,
D. M., Neeman, M., Sessa, W. C.,
Dvorak, H. F., and Benjamin, L. E.
(2006). Pathological angiogenesis is
induced by sustained Akt signaling
and inhibited by rapamycin. Cancer
Cell 10, 159–170.
Pitulescu, M. E., and Adams, R.
H. (2010). Eph/ephrin molecules–a
hub for signaling and endocytosis.
Genes Dev. 24, 2480–2492.
Pore, N., Gupta, A. K., Cerniglia, G.
J., and Maity, A. (2006a). HIV pro-
teaseinhibitorsdecreaseVEGF/HIF-
1alpha expression and angiogenesis
in glioblastoma cells. Neoplasia 8,
889–895.
Pore, N., Jiang, Z., Gupta, A., Cerniglia,
G.,Kao,G.D.,andMaity,A.(2006b).
EGFR tyrosine kinase inhibitors
decrease VEGF expression by both
hypoxia-inducible factor (HIF)-1-
independent and HIF-1-dependent
mechanisms. Cancer Res. 66,
3197–3204.
Pore, N., Liu, S., Haas-Kogan, D. A.,
O’Rourke, D. M., and Maity, A.
(2003). PTEN mutation and epi-
dermal growth factor receptor acti-
vation regulate vascular endothe-
lial growth factor (VEGF) mRNA
expression in human glioblastoma
cells by transactivating the proxi-
malVEGF promoter. Cancer Res. 63,
236–241.
Primo, L., di, B. L., Roca, C., Droetto,
S., Piva, R., Schaffhausen, B., and
Bussolino, F. (2007). Essential role
of PDK1 in regulating endothe-
lial cell migration. J. Cell Biol. 176,
1035–1047.
Rak, J., Mitsuhashi, Y., Bayko, L., Fil-
mus, J., Shirasawa, S., Sasazuki,
T., and Kerbel, R. S. (1995).
Mutant ras oncogenes upregulate
VEGF/VPF expression: implications
for induction and inhibition of
tumor angiogenesis. Cancer Res. 55,
4575–4580.
Ratcliffe,P.J.,Pugh,C.W.,andMaxwell,
P. H. (2000). Targeting tumors
through the HIF system. Nat. Med.
6, 1315–1316.
Raynaud, F. I., Eccles, S., Clarke, P. A.,
Hayes,A.,Nutley,B.,Alix,S.,Henley,
A., Di-Stefano, F., Ahmad, Z., Guil-
lard, S., Bjerke, L. M., Kelland, L.,
Valenti,M.,Patterson,L.,Gowan,S.,
de Haven Brandon, A., Hayakawa,
M.,Kaizawa,H.,Koizumi,T.,Ohishi,
T., Patel, S., Saghir, N., Parker, P.,
Waterﬁeld, M., and Workman, P.
(2007).Pharmacologiccharacteriza-
tion of a potent inhibitor of class
I phosphatidylinositide 3-kinases.
Cancer Res. 67, 5840–5850.
Rodriguez-Viciana, P., Warne, P. H.,
Dhand, R., Vanhaesebroeck, B.,
Gout, I., Fry, M. J., Waterﬁeld,
M. D., and Downward, J. (1994).
Phosphatidylinositol-3-OH kinase
as a direct target of Ras. Nature 370,
527–532.
Saharinen, P., Eklund, L., Miettinen, J.,
Wirkkala, R., Anisimov, A., Winder-
lich, M., Nottebaum, A., Vestwe-
ber, D., Deutsch, U., Koh, G. Y.,
Olsen, B. R., and Alitalo, K. (2008).
AngiopoietinsassembledistinctTie2
signalling complexes in endothelial
cell-cell and cell-matrix contacts.
Nat. Cell Biol. 10, 527–537.
Sarbassov, D. D., Ali, S. M., Sengupta,
S., Sheen, J. H., Hsu, P. P., Bagley,
A. F., Markhard, A. L., and Sabatini,
D. M. (2006). Prolonged rapamycin
treatment inhibits mTORC2 assem-
bly and Akt/PKB. Mol. Cell 22,
159–168.
Sawamiphak, S., Seidel, S., Essmann,
C. L., Wilkinson, G. A., Pitulescu,
M. E., Acker, T., and Acker-Palmer,
A. (2010). Ephrin-B2 regulates
VEGFR2 function in developmen-
talandtumourangiogenesis.Nature
465, 487–491.
Schnell, C. R., Stauffer, F., Allegrini,
P. R., O’Reilly, T., McSheehy,
P. M., Dartois, C., Stumm, M.,
Cozens, R., Littlewood-Evans,
A., García-Echeverría, C., and
Maira, S. M. (2008). Effects of
the dual phosphatidylinositol
3-kinase/mammalian target of
rapamycin inhibitor NVP-BEZ235
on the tumor vasculature: implica-
tions for clinical imaging. Cancer
Res. 68, 6598–6607.
Semenza, G. L. (2003). Targeting HIF-1
for cancer therapy. Nat. Rev. Cancer
3, 721–732.
Serban, D., Leng, J., and Cheresh,
D. (2008). H-ras regulates angio-
genesis and vascular permeability
by activation of distinct down-
stream effectors. Circ. Res. 102,
1350–1358.
Serra, V., Markman, B., Scaltriti, M.,
Eichhorn, P. J., Valero, V., Guzman,
M.,Botero,M. L.,Llonch,E.,Atzori,
F.,Di Cosimo,S.,Maira,M.,Garcia-
Echeverria,C.,Parra,J.L.,Arribas,J.,
andBaselga,J.(2008).NVP-BEZ235,
a dual PI3K/mTOR inhibitor, pre-
ventsPI3Ksignalingandinhibitsthe
growth of cancer cells with activat-
ing PI3K mutations. Cancer Res. 68,
8022–8030.
Tian, T., Nan, K. J., Wang, S. H., Liang,
X., Lu, C. X., Guo, H., Wang, W.
J., and Ruan, Z. P. (2010). PTEN
regulates angiogenesis and VEGF
expression through phosphatase-
dependent and -independent mech-
anisms in HepG2 cells. Carcinogene-
sis 31, 1211–1219.
Toker, A., and Cantley, L. C. (1997).
Signalling through the lipid
products of phosphoinositide-
3-OH kinase. Nature 387,
673–676.
Tran, J., Master, Z., Yu, J. L., Rak,
J., Dumont, D. J., and Kerbel, R.
S. (2002). A role for survivin in
chemoresistance of endothelial cells
mediated byVEGF. Proc. Natl. Acad.
Sci. U.S.A. 99, 4349–4354.
Tran, J., Rak, J., Sheehan, C., Saibil, S.
D., LaCasse, E., Korneluk, R. G., and
Kerbel, R. S. (1999). Marked induc-
tion of the IAP family antiapop-
totic proteins survivin and XIAP
by VEGF in vascular endothelial
cells. Biochem. Biophys. Res. Com-
mun. 264, 781–788.
Vaupel, P., Kallinowski, F., and Oku-
nieff, P. (1989). Blood ﬂow, oxy-
gen and nutrient supply, and meta-
bolic microenvironment of human
tumors: a review. Cancer Res. 49,
6449–6465.
Viloria-Petit, A., Crombet, T., Jothy, S.,
Hicklin, D., Bohlen, P., Schlaeppi, J.
M., Rak, J., and Kerbel, R. S. (2001).
Acquired resistance to the antitu-
mor effect of epidermal growth
factor receptor-blocking antibod-
ies in vivo: a role for altered
tumor angiogenesis. Cancer Res. 61,
5090–5101.
Wang, F., Yamauchi, M., Muramatsu,
M., Osawa, T., Tsuchida, R., and
Shibuya, M. (2011). RACK1 reg-
ulates VEGF/Flt1-mediated cell
migration via activation of a
PI3K/Akt pathway. J. Biol. Chem.
286, 9097–9106.
Wang, Y., Nakayama, M., Pitulescu, M.
E., Schmidt, T. S., Bochenek, M.
L., Sakakibara, A., Adams, S., Davy,
A., Deutsch, U., Lüthi, U., Bar-
beris, A., Benjamin, L. E., Mäki-
nen, T., Nobes, C. D., and Adams,
R. H. (2010). Ephrin-B2 con-
trols VEGF-induced angiogenesis
andlymphangiogenesis.Nature 465,
483–486.
Whitman, M., Downes, C. P., Keeler,
M., Keller, T., and Cantley, L.
(1988). Type I phosphatidylinosi-
tol kinase makes a novel inositol
phospholipid, phosphatidylinositol-
3-phosphate. Nature 332, 644–646.
Xu, Q., Briggs, J., Park, S., Niu, G.,
Kortylewski, M., Zhang, S., Gritsko,
T., Turkson, J., Kay, H., Semenza,
G. L., Cheng, J. Q., Jove, R., and
Yu,H.(2005).TargetingStat3blocks
both HIF-1 and VEGF expres-
sion induced by multiple oncogenic
growth signaling pathways. Onco-
gene 24, 5552–5560.
Yuan, H. T., Khankin, E. V., Karu-
manchi, S. A., and Parikh, S. M.
(2009). Angiopoietin 2 is a partial
agonist/antagonist of Tie2 signaling
in the endothelium. Mol. Cell. Biol.
29, 2011–2022.
Zhang, J., Fukuhara, S., Sako, K.,
Takenouchi, T., Kitani, H., Kume,
T., Koh, G. Y., and Mochizuki,
N. (2011). Angiopoietin-1/Tie2 sig-
nal augments basal Notch signal
controlling vascular quiescence by
inducing delta-like 4 expression
through AKT-mediated activation
of beta-catenin. J. Biol. Chem. 286,
8055–8066.
Zhao, P., Meng, Q., Liu, L. Z.,
You, Y. P., Liu, N., and Jiang,
B. H. (2010). Regulation of sur-
vivin by PI3K/Akt/p70S6K1 path-
way. Biochem. Biophys. Res. Com-
mun. 395, 219–224.
Zhong,H.,Chiles,K.,Feldser,D.,Laugh-
ner,E.,Hanrahan,C.,Georgescu,M.
M., Simons, J. W., and Semenza, G.
L. (2000). Modulation of hypoxia-
inducible factor 1alpha expres-
sion by the epidermal growth
Frontiers in Molecular Neuroscience www.frontiersin.org December 2011 | Volume 4 | Article 51 | 7Karar and Maity PI3K/AKT/mTOR pathway in angiogenesis
factor/phosphatidylinositol 3-
kinase/PTEN/AKT/FRAP pathway
in human prostate cancer cells:
implications for tumor angiogenesis
and therapeutics. Cancer Res. 60,
1541–1545.
Zundel, W., Schindler, C., Haas-Kogan,
D., Koong, A., Kaper, F., Chen, E.,
Gottschalk,A. R., Ryan, H. E., John-
son, R. S., Jefferson, A. B., Stokoe,
D., and Giaccia, A. J. (2000). Loss
of PTEN facilitates HIF-1-mediated
gene expression. Genes Dev. 14,
391–396.
Zwerts, F., Lupu, F., De Vriese, A.,
Pollefeyt, S., Moons, L., Altura, R.
A., Jiang, Y., Maxwell, P. H., Hill,
P., Oh, H., Rieker, C., Collen, D.,
Conway, S. J., and Conway, E. M.
(2007). Lack of endothelial cell
survivin causes embryonic defects
in angiogenesis, cardiogenesis, and
neural tube closure. Blood 109,
4742–4752.
Conﬂict of Interest Statement:
The authors declare that the
research was conducted in the
absence of any commercial or
ﬁnancial relationships that could
be construed as a potential conﬂict of
interest.
Received: 01 August 2011; accepted: 15
November 2011; published online: 02
December 2011.
Citation: Karar J and Maity A (2011)
PI3K/AKT/mTORpathwayinangiogen-
esis. Front. Mol. Neurosci. 4:51. doi:
10.3389/fnmol.2011.00051
Copyright©2011Karar andMaity.This
is an open-access article subject to a non-
exclusive license between the authors and
Frontiers Media SA, which permits use,
distribution and reproduction in other
forums,providedtheoriginalauthorsand
source are credited and other Frontiers
conditions are complied with.
Frontiers in Molecular Neuroscience www.frontiersin.org December 2011 | Volume 4 | Article 51 | 8